Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Oncology News

ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.

Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.

1568 results

15 Jan 2019

Cytotoxic Therapy; Haematological Malignancies

FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL

14 Jan 2019

Targeted Therapy; Breast Cancer

NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer

EndoPredict, Oncotype DX Breast Recurrence Score and Prosigna are recommended, while MammaPrint and IHC4+C are not

11 Jan 2019

Cytotoxic Therapy; Haematological Malignancies

FDA Approves Tagraxofusp-erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm

CD123-directed cytotoxin is indicated in adults and in paediatric patients

10 Jan 2019

Targeted Therapy

Spotlight on Digital Medicine

A series of articles published in the Nature Medicine highlight new technologies that are transforming medicine and healthcare

09 Jan 2019

Immunotherapy; Skin Cancers

FDA Approves Pembrolizumab for Merkel Cell Carcinoma

Approval is based on results from the KEYNOTE-017 study

08 Jan 2019

Targeted Therapy; Cytotoxic Therapy; Gynaecological Malignancies

FDA Approves Olaparib for First-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer

Patients should be selected for therapy based on an FDA-approved companion diagnostic

07 Jan 2019

Cytotoxic Therapy; Breast Cancer

FDA Approves Herzuma as a Biosimilar to Herceptin

Herzuma is indicated for the treatment of HER2-overexpressing breast cancer